A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
Open Access
- 16 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 59 (11), 1665-1674
- https://doi.org/10.1007/s00262-010-0892-3
Abstract
Screening a phage-display single-chain antibody library for binding to the breast cancer cell line PM-1 an antibody, scFv173, recognising activated leukocyte cell adhesion molecule (ALCAM, CD166) was isolated and its binding profile was characterized. Positive ALCAM immunohistochemical staining of frozen human tumour sections was observed. No ALCAM staining was observed in the majority of tested normal human tissues (nine of ten). Flow cytometry analyses revealed binding to 22 of 26 cancer cell lines of various origins and no binding to normal blood and bone marrow cells. Antibody binding inhibited invasion of the breast cancer cell line MDA-MB-231 by 50% in an in vitro Matrigel-coated membrane invasion assay. Reduced growth of tumours in nude mice was observed in an in vivo model in which the mice were injected subcutaneously with colorectal carcinoma HCT 116 cells and treated with scFv173 when compared to control. In summary, we have characterized a novel fully human scFv antibody recognising ALCAM on cancer cells and in tumour tissues that reduces cancer cell invasion and tumour growth in accordance with the hypothesised role for ALCAM in cell growth and migration control.Keywords
This publication has 36 references indexed in Scilit:
- Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapseBritish Journal of Cancer, 2009
- Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeuticProceedings of the National Academy of Sciences of the United States of America, 2008
- Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma PatientsClinical Cancer Research, 2008
- Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancerBreast Cancer Research and Treatment, 2008
- Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration?Cancer and Metastasis Reviews, 2005
- Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude miceEuropean Journal Of Cancer, 2004
- Activated leukocyte cell adhesion molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migrationEuropean Journal of Cell Biology, 2002
- Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastomaInternational Journal of Cancer, 1986
- Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell lineFEBS Letters, 1986
- Chemosensitivity profiles of human cancers assessed by the 6‐day SRC assay on serially xenografted tumorsInternational Journal of Cancer, 1986